

Scott M Grundy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8596839/publications.pdf>

Version: 2024-02-01

213
papers

106,533
citations

1799

103
h-index

1568

217
g-index

230
all docs

230
docs citations

230
times ranked

71491
citing authors

#	ARTICLE	IF	CITATIONS
1	Statin Intolerance and Noncompliance: An Empiric Approach. American Journal of Medicine, 2022, 135, 318-323.	1.5	5
2	Prevalence and significance of risk enhancing biomarkers in the United States population at intermediate risk for atherosclerotic disease. Journal of Clinical Lipidology, 2022, 16, 66-74.	1.5	4
3	Managing Atherosclerotic Cardiovascular Risk in Young Adults. Journal of the American College of Cardiology, 2022, 79, 819-836.	2.8	72
4	Statin Therapy for Primary Prevention in Women: What is the Role for Coronary Artery Calcium?. Journal of Clinical Lipidology, 2022, , .	1.5	2
5	Chronic kidney disease and statin eligibility. Journal of Clinical Lipidology, 2021, 15, 173-180.	1.5	6
6	Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. Journal of Clinical Lipidology, 2021, 15, 255-265.	1.5	6
7	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Progress in Cardiovascular Diseases, 2021, 68, 2-6.	3.1	9
8	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. American Journal of Medicine, 2021, 134, 1091-1095.	1.5	3
9	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clinic Proceedings, 2021, 96, 2660-2670.	3.0	7
10	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. Diabetes Care, 2020, 43, 1673-1678.	8.6	31
11	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
12	Temporal decline in nonâ€“high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2020, 14, 425-430.	1.5	3
13	Treating Hypercholesterolemia in Older Adults. JAMA - Journal of the American Medical Association, 2019, 322, 695.	7.4	1
14	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology, 2019, 74, 712-714.	2.8	21
15	Current trends in nonâ€“HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2019, 13, 563-567.	1.5	17
16	Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines. Journal of Clinical Lipidology, 2019, 13, 356-359.	1.5	8
17	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterolâ€“Secondary Prevention. JAMA Cardiology, 2019, 4, 589.	6.1	38
18	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 473.	6.1	1

#	ARTICLE	IF	CITATIONS
19	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiology, 2019, 4, 488.	6.1	33
20	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline*. Annals of Internal Medicine, 2019, 170, 779.	3.9	38
21	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Progress in Cardiovascular Diseases, 2019, 62, 375-383.	3.1	32
22	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 2019, 73, e285-e350.	2.8	1,550
23	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 139, e1082-e1143.	1.6	2,380
24	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology, 2019, 73, 3168-3209.	2.8	1,128
25	Upper body fat predicts metabolic syndrome similarly in men and women. European Journal of Clinical Investigation, 2018, 48, e12941.	3.4	18
26	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2018, 138, 2315-2325.	1.6	154
27	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer. Mayo Clinic Proceedings, 2017, 92, 536-543.	3.0	9
28	Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. Journal of the Endocrine Society, 2017, 1, 1417-1427.	0.2	22
29	Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate. Cell Metabolism, 2016, 23, 755-757.	16.2	6
30	Fatty acid oxidation in normotriglyceridemic men. Journal of Clinical Lipidology, 2016, 10, 283-288.	1.5	10
31	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA - Journal of the American Medical Association, 2016, 316, 1289.	7.4	974
32	Overnutrition, Ectopic Lipid and the Metabolic Syndrome. Journal of Investigative Medicine, 2016, 64, 1082-1086.	1.6	62
33	Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men. Journal of Clinical Lipidology, 2016, 10, 1414-1422.e1.	1.5	11
34	Does Dietary Cholesterol Matter?. Current Atherosclerosis Reports, 2016, 18, 68.	4.8	39
35	Advances in treatment of dyslipidaemia. Nature Reviews Cardiology, 2016, 13, 74-75.	13.7	10
36	Metabolic syndrome update. Trends in Cardiovascular Medicine, 2016, 26, 364-373.	4.9	576

#	ARTICLE	IF	CITATIONS
37	Adipose tissue and metabolic syndrome: too much, too little or neither. European Journal of Clinical Investigation, 2015, 45, 1209-1217.	3.4	129
38	Is There a Gradient of Mortality Risk among Men with Low Cardiorespiratory Fitness?. Medicine and Science in Sports and Exercise, 2015, 47, 1825-1832.	0.4	17
39	Cholesterol Efflux Capacity as a Therapeutic Target. Journal of the American College of Cardiology, 2015, 66, 2211-2213.	2.8	17
40	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	1.5	430
41	Reply. Journal of the American College of Cardiology, 2015, 65, 760-761.	2.8	2
42	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	1.5	632
43	Next Steps in Primary Prevention of Coronary Heart Disease. Journal of the American College of Cardiology, 2015, 66, 1828-1836.	2.8	50
44	Perspectives on Cholesterol Guidelines. Contemporary Endocrinology, 2015, , 313-327.	0.1	0
45	The CardioMetabolic Health Alliance. Journal of the American College of Cardiology, 2015, 66, 1050-1067.	2.8	211
46	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. PLoS ONE, 2014, 9, e114519.	2.5	38
47	Statins: Definitive Translational Research. Molecular Medicine, 2014, 20, S20-S23.	4.4	7
48	Cholesterol Management in Older Persons. American Journal of Medicine, 2014, 127, 1140-1141.	1.5	8
49	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. Journal of Clinical Lipidology, 2014, 8, 29-60.	1.5	289
50	Ethnic and Gender Susceptibility to Metabolic Risk. Metabolic Syndrome and Related Disorders, 2014, 12, 110-116.	1.3	17
51	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	2.8	512
52	2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Bloodâ€”Cholesterol. Journal of the American College of Cardiology, 2014, 64, 601-612.	2.8	58
53	Statins for All?. American Journal of Cardiology, 2014, 114, 1443-1446.	1.6	8
54	An assessment by the Statin Intolerance Panel: 2014 update. Journal of Clinical Lipidology, 2014, 8, S72-S81.	1.5	135

#	ARTICLE	IF	CITATIONS
55	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 561-565.	1.5	147
56	Plasma noncholesterol sterols as indicators of cholesterol absorption. <i>Journal of Lipid Research</i> , 2013, 54, 873-875.	4.2	14
57	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. <i>Obesity</i> , 2013, 21, E439-47.	3.0	355
58	Metabolic Risk Susceptibility in Men Is Partially Related to Adiponectin/Leptin Ratio. <i>Journal of Obesity</i> , 2013, 2013, 1-9.	2.7	85
59	Waist Circumference as Measure of Abdominal Fat Compartments. <i>Journal of Obesity</i> , 2013, 2013, 1-9.	2.7	64
60	Cardiorespiratory Fitness, LDL Cholesterol, and CHD Mortality in Men. <i>Medicine and Science in Sports and Exercise</i> , 2012, 44, 2132-2137.	0.4	30
61	Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese Adults. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1150.	7.4	500
62	Use of Emerging Lipoprotein Risk Factors in Assessment of Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2540-2.	7.4	16
63	Influence of Upper and Lower Body Adipose Tissue on Insulin Sensitivity in South Asian Men. <i>Journal of Investigative Medicine</i> , 2012, 60, 999-1004.	1.6	16
64	Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2012, 59, 635-643.	2.8	477
65	Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. <i>Current Cardiology Reports</i> , 2012, 14, 692-700.	2.9	3
66	Cardiorespiratory Fitness and Metabolic Risk. <i>American Journal of Cardiology</i> , 2012, 109, 988-993.	1.6	64
67	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Circulation</i> , 2011, 124, 2458-2473.	1.6	1,369
68	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2432-2446.	2.8	700
69	Clinical Characteristics, Vascular Function, and Inflammation in Women With Angina in the Absence of Coronary Atherosclerosis. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 65-73.	5.3	19
70	Comparisons of Apolipoprotein B Levels Estimated by Immunoassay, Nuclear Magnetic Resonance, Vertical Auto Profile, and Non-High-Density Lipoprotein Cholesterol in Subjects With Hypertriglyceridemia (SAFARI Trial). <i>American Journal of Cardiology</i> , 2011, 108, 40-46.	1.6	29
71	Effect of Colesevelam Hydrochloride on Glycemia and Insulin Sensitivity in Men With the Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1129-1135.	1.6	22
72	Can we dramatically reduce the incidence of coronary heart disease?. <i>Nature Reviews Cardiology</i> , 2011, 8, 721-725.	13.7	40

#	ARTICLE	IF	CITATIONS
73	Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2264-2276.	2.4	369
74	Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 800-809.	3.6	70
75	The metabolic syndrome. Lancet, The, 2010, 375, 181-183.	13.7	2,488
76	Harmonizing the Metabolic Syndrome. Circulation, 2009, 120, 1640-1645.	1.6	11,462
77	Sex Differences in the Relationship between C-Reactive Protein and Body Fat. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3251-3258.	3.6	136
78	Correlation of Non-HDL High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial). American Journal of Cardiology, 2009, 104, 548-553.	1.6	41
79	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study). American Journal of Cardiology, 2009, 103, 1694-1702.	1.6	62
80	Ethnic differences in hepatic steatosis: An insulin resistance paradox?. Hepatology, 2009, 49, 791-801.	7.3	309
81	Advancing drug therapy of the metabolic syndrome. Nature Reviews Drug Discovery, 2009, 8, 341-341.	46.4	8
82	Evaluation of coronary artery calcium screening strategies focused on risk categories: The Dallas Heart Study. American Heart Journal, 2009, 157, 1001-1009.	2.7	10
83	Impaired Hepatic Ketogenesis in Moderately Obese Men With Hypertriglyceridemia. Journal of Investigative Medicine, 2009, 57, 590-594.	1.6	8
84	Metabolic Syndrome Pandemic. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 629-636.	2.4	1,202
85	Promise of Low-Density Lipoprotein Lowering Therapy for Primary and Secondary Prevention. Circulation, 2008, 117, 569-573.	1.6	45
86	A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. Country Review Ukraine, 2008, 10, B16-B23.	0.8	20
87	Thyroid mimetic as an option for lowering low-density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 409-410.	7.1	4
88	Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. Diabetes and Vascular Disease Research, 2008, 5, 96-101.	2.0	57
89	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	1.6	405
90	Variable Contributions of Fat Content and Distribution to Metabolic Syndrome Risk Factors. Metabolic Syndrome and Related Disorders, 2008, 6, 281-288.	1.3	41

#	ARTICLE	IF	CITATIONS
91	Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2043-2049.	2.4	99
92	Metabolic Syndrome Phenotype in Very Obese Women. Metabolic Syndrome and Related Disorders, 2007, 5, 3-12.	1.3	4
93	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. BMJ: British Medical Journal, 2007, 334, 982-982.	2.3	16
94	ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. Circulation, 2007, 115, 402-426.	1.6	552
95	Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome. Journal of Investigative Medicine, 2007, 55, 237-247.	1.6	14
96	Cardiovascular and Metabolic Risk Factors: How Can We Improve Outcomes in the High-Risk Patient?. American Journal of Medicine, 2007, 120, S3-S8.	1.5	38
97	Sex differences in the association between leptin and CRP: Results from the Dallas Heart Study. Atherosclerosis, 2007, 195, 404-410.	0.8	62
98	ACCF/AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. Journal of the American College of Cardiology, 2007, 49, 378-402.	2.8	891
99	The Association of Differing Measures of Overweight and Obesity With Prevalent Atherosclerosis. Journal of the American College of Cardiology, 2007, 50, 752-759.	2.8	156
100	Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 399-404.	3.6	566
101	Insulin Resistance and Body Fat Distribution in South Asian Men Compared to Caucasian Men. PLoS ONE, 2007, 2, e812.	2.5	190
102	Reply to AM Zivkovic and JB German. American Journal of Clinical Nutrition, 2007, 85, 241-242.	4.7	0
103	Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology, 2007, 46, 716-722.	7.3	78
104	Harmonizing the Definition of the Metabolic Syndrome: Comparison of the Criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European Populations. American Journal of Cardiology, 2007, 99, 541-548.	1.6	128
105	Management of Cholesterol Disorders. , 2007, , 2667-2691.		0
106	Influence of Body Fat Content and Distribution on Variation in Metabolic Risk. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4459-4466.	3.6	270
107	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet, The, 2006, 368, 919-928.	13.7	369
108	Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds. Journal of the American College of Cardiology, 2006, 47, 1093-1100.	2.8	524

#	ARTICLE	IF	CITATIONS
109	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <i>Current Therapeutic Research</i> , 2006, 67, 321-333.	1.2	1
110	Does a diagnosis of metabolic syndrome have value in clinical practice?1,2. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 1248-1251.	4.7	146
111	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 295-309.	46.4	230
112	Metabolic Syndrome and Hyperglycemia: Congruence and Divergence. <i>American Journal of Cardiology</i> , 2006, 98, 982-985.	1.6	36
113	Non-HDL High-Density Lipoprotein and Very-Low-Density Lipoprotein Cholesterol and Their Risk Predictive Values in Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2006, 98, 1363-1368.	1.6	245
114	Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. <i>Clinical Cornerstone</i> , 2006, 8, S21-S27.	0.7	81
115	Relationship Between C-Reactive Protein and Subclinical Atherosclerosis. <i>Circulation</i> , 2006, 113, 38-43.	1.6	184
116	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. <i>Circulation</i> , 2006, 113, 2363-2372.	1.6	1,742
117	Does the Metabolic Syndrome Exist?. <i>Diabetes Care</i> , 2006, 29, 1689-1692.	8.6	151
118	Multiple rare variants in <i>NPC1L1</i> associated with reduced sterol absorption and plasma low-density lipoprotein levels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1810-1815.	7.1	380
119	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006, 29, 1220-1226.	8.6	493
120	Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). <i>American Journal of Cardiology</i> , 2005, 95, 194-198.	1.6	63
121	Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI) Tj ETQq1 1 0.784314 rrgBT /Ov	1.6	290
122	Stanol Esters as a Component of Maximal Dietary Therapy in the National Cholesterol Education Program Adult Treatment Panel III Report. <i>American Journal of Cardiology</i> , 2005, 96, 47-50.	1.6	52
123	A constellation of complications:The metabolic syndrome. <i>Clinical Cornerstone</i> , 2005, 7, 36-45.	0.7	76
124	Point: The Metabolic Syndrome Still Lives. <i>Clinical Chemistry</i> , 2005, 51, 1352-1354.	3.2	64
125	The metabolic syndrome. <i>Lancet</i> , The, 2005, 365, 1415-1428.	13.7	5,212
126	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , 2005, 112, 2735-2752.	1.6	9,757

#	ARTICLE	IF	CITATIONS
127	Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without Diabetes. <i>Diabetes Care</i> , 2005, 28, 1916-1921.	8.6	246
128	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , 2005, 112, .	1.6	332
129	The Issue of Statin Safety. <i>Circulation</i> , 2005, 111, 3016-3019.	1.6	87
130	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2005, 352, 1425-1435.	27.0	3,152
131	Atherosclerosis Imaging and the Future of Lipid Management. <i>Circulation</i> , 2004, 110, 3509-3511.	1.6	20
132	Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?. <i>Circulation</i> , 2004, 109, 2818-2825.	1.6	578
133	Adipose Tissue Metabolites and Insulin Resistance in Nondiabetic Asian Indian Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2750-2755.	3.6	165
134	No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2326-2332.	2.4	167
135	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Circulation</i> , 2004, 110, 227-239.	1.6	5,602
136	Definition of Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e13-8.	2.4	627
137	Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure. <i>Diabetes Care</i> , 2004, 27, 256-263.	8.6	561
138	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. <i>Hepatology</i> , 2004, 40, 1387-1395.	7.3	3,250
139	What is the contribution of obesity to the metabolic syndrome?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, 267-282.	3.2	70
140	African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1011-1017.	2.8	171
141	Definition of Metabolic Syndrome. <i>Circulation</i> , 2004, 109, 433-438.	1.6	4,617
142	Obesity, Metabolic Syndrome, and Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2595-2600.	3.6	1,056
143	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004, 44, 720-732.	2.8	1,207
144	Metabolic syndrome: Part II. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004, 33, xi-xiii.	3.2	4

145	Metabolic syndrome: Part I. Endocrinology and Metabolism Clinics of North America, 2004, 33, ix-xi.	3.2	5
146	Metabolic syndrome: what is it and how should I treat it?. ACC Current Journal Review, 2003, 12, 37-40.	0.1	3
147	Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. American Journal of Cardiology, 2003, 91, 956-960.	1.6	163
148	Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease. Progress in Cardiovascular Diseases, 2003, 46, 115-121.	3.1	8
149	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. Mayo Clinic Proceedings, 2003, 78, 965-978.	3.0	410
150	Genetic Polymorphism PC-1 K121Q and Ethnic Susceptibility to Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5927-5934.	3.6	119
151	Elevated Plasma High-Sensitivity C-Reactive Protein Concentrations in Asian Indians Living in the United States. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3773-3776.	3.6	109
152	The Metabolic Syndrome. Circulation, 2003, 108, 1537-1540.	1.6	87
153	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. Mayo Clinic Proceedings, 2003, 78, 965-978.	3.0	855
154	Statin Therapy in Older Persons. Archives of Internal Medicine, 2002, 162, 1329.	3.8	22
155	Obesity, Metabolic Syndrome, and Coronary Atherosclerosis. Circulation, 2002, 105, 2696-2698.	1.6	303
156	Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes_{title>}Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial_{title>}. Archives of Internal Medicine, 2002, 162, 1568.	3.8	507
157	Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy. Circulation, 2002, 106, 2526-2529.	1.6	259
158	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation, 2002, 106, 1024-1028.	1.6	657
159	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Circulation, 2002, 106, 388-391.	1.6	1,623
160	Diet composition and the metabolic syndrome: what is the optimal fat intake?. American Journal of Medicine, 2002, 113, 25-29.	1.5	117
161	ACC/AHA/NHLBI clinical advisory on the use and safety of statins_{1>}When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568-573.22This document is available on the Web sites of the ACC (www.acc.org), the		

#	ARTICLE	IF	CITATIONS
163	Alternative approaches to cholesterol-lowering therapy. American Journal of Cardiology, 2002, 90, 1135-1138.	1.6	13
164	AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Journal of the American College of Cardiology, 2001, 38, 1581-1583.	2.8	319
165	Non-HDL High-Density Lipoprotein Cholesterol Level as Potential Risk Predictor and Therapy Target. Archives of Internal Medicine, 2001, 161, 1379.	3.8	36
166	Coronary plaque as a replacement for age as a risk factor in global risk assessment. American Journal of Cardiology, 2001, 88, 8-11.	1.6	88
167	United states cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein-cholesterol lowering therapy. American Journal of Cardiology, 2001, 88, 23-27.	1.6	103
168	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. Circulation, 2001, 104, 1577-1579.	1.6	564
169	Validation of the Framingham Coronary Heart Disease Prediction Scores. JAMA - Journal of the American Medical Association, 2001, 286, 180.	7.4	1,798
170	Dietary Fat: At the Heart of the Matter. Science, 2001, 293, 801d-804.	12.6	16
171	Metabolic Complications of Obesity. Endocrine, 2000, 13, 155-165.	2.2	174
172	American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease. Circulation, 2000, 102, 126-140.	1.6	664
173	American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Journal of the American College of Cardiology, 2000, 36, 326-340.	2.8	488
174	Primary Prevention of Coronary Heart Disease. Circulation, 1999, 100, 988-998.	1.6	204
175	Hepatic Lipase (LIPC) Promoter Polymorphism in Men With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1975-1978.	2.4	51
176	Diabetes and Cardiovascular Disease. Circulation, 1999, 100, 1134-1146.	1.6	1,903
177	Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. Journal of the American College of Cardiology, 1999, 34, 1348-1359.	2.8	368
178	Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. American Journal of Cardiology, 1998, 81, 18B-25B.	1.6	451
179	Statin Trials and Goals of Cholesterol-Lowering Therapy. Circulation, 1998, 97, 1436-1439.	1.6	187
180	Cholesterol management in high-risk patients without heart disease. Postgraduate Medicine, 1998, 104, 117-129.	2.0	5

#	ARTICLE	IF	CITATIONS
181	Three polymorphisms associated with low hepatic lipase activity are common in African Americans. Journal of Lipid Research, 1998, 39, 1900-1903.	4.2	27
182	Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. Journal of Lipid Research, 1998, 39, 1127-1130.	4.2	60
183	Hepatic lipase activity is lower in African American men than in white American men: effects of 5â€² flanking polymorphism in the hepatic lipase gene (LIPC). Journal of Lipid Research, 1998, 39, 228-232.	4.2	139
184	Relationship of Anterior and Posterior Subcutaneous Abdominal Fat to Insulin Sensitivity in Nondiabetic Men. Obesity, 1997, 5, 93-99.	4.0	178
185	Cholesterol management in patients with heart disease. Postgraduate Medicine, 1997, 102, 81-90.	2.0	11
186	Small LDL, Atherogenic Dyslipidemia, and the Metabolic Syndrome. Circulation, 1997, 95, 1-4.	1.6	288
187	Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Current Opinion in Lipidology, 1996, 7, 209-216.	2.7	75
188	Cholesterolâ€raising effects of coffee: clues to regulation of cholesterol metabolism. Journal of Internal Medicine, 1995, 238, 475-477.	6.0	4
189	Oxidized LDL and atherogenesis: Relation to risk factors for coronary heart disease. Clinical Cardiology, 1993, 16, 3-5.	1.8	23
190	Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel) Tj ETQq0 0 0 rBT /Overdork110 Tf	7.8	110
191	Reply to KC Hayes. American Journal of Clinical Nutrition, 1993, 57, 232.	4.7	0
192	Reply to ML Goldberg and MG Enig. American Journal of Clinical Nutrition, 1993, 58, 244.	4.7	0
193	Recent Nutrition Research: Implications for Foods of the Future. Annals of Medicine, 1991, 23, 187-193.	3.8	17
194	Drug Therapy in Dyslipidemia. Scandinavian Journal of Clinical and Laboratory Investigation, 1990, 50, 63-72.	1.2	1
195	Cholesterol and Coronary Heart Disease. Scandinavian Journal of Clinical and Laboratory Investigation, 1990, 50, 17-24.	1.2	61
196	Treatment of diabetic dyslipidaemia. Biochemical Society Transactions, 1989, 17, 56-58.	3.4	2
197	Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. Clinical Pharmacology and Therapeutics, 1988, 44, 297-302.	4.7	5
198	Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover. Journal of Pediatrics, 1988, 113, 387-392.	1.8	83

#	ARTICLE	IF	CITATIONS
199	HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia. New England Journal of Medicine, 1988, 319, 24-33.	27.0	762
200	Fibric acids: Effects on lipids and lipoprotein metabolism. American Journal of Medicine, 1987, 83, 9-20.	1.5	186
201	Accumulation of 7 β -hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: Effect of treatment with chenodeoxycholic acid. Hepatology, 1987, 7, 266-271.	7.3	49
202	Comparison of Monounsaturated Fatty Acids and Carbohydrates for Lowering Plasma Cholesterol. New England Journal of Medicine, 1986, 314, 745-748.	27.0	716
203	Cholesterol and Coronary Heart Disease. JAMA - Journal of the American Medical Association, 1986, 256, 2849.	7.4	254
204	Effects of AOMA on cholesterol metabolism in man. Metabolism: Clinical and Experimental, 1982, 31, 733-739.	3.4	29
205	The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. Journal of Chronic Diseases, 1980, 33, 679-684.	1.2	39
206	Effects of sucrose polyester on cholesterol metabolism in man. Metabolism: Clinical and Experimental, 1979, 28, 994-1000.	3.4	83
207	Transport of Very Low Density Lipoprotein Triglycerides in Varying Degrees of Obesity and Hypertriglyceridemia. Journal of Clinical Investigation, 1979, 63, 1274-1283.	8.2	257
208	Plant sterols as cholesterol-lowering agents: Clinical trials in patients with hypercholesterolemia and studies of sterol balance. Atherosclerosis, 1977, 28, 325-338.	0.8	326
209	Chylomicron clearance in normal and hyperlipidemic man. Metabolism: Clinical and Experimental, 1976, 25, 1225-1239.	3.4	221
210	A Physiological Method for Estimation of Hepatic Secretion of Biliary Lipids in Man. Gastroenterology, 1972, 62, 1200-1217.	1.3	236
211	Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. Journal of Lipid Research, 1972, 13, 531-551.	4.2	293
212	Dietary β -sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. Journal of Lipid Research, 1968, 9, 374-387.	4.2	243
213	Cholesterol Management in the Context of Risk Factor Profile. , 0, , 187-195.		0